Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Event, Webcast

Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 10:00 a.m. ET.

A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta's research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.


These press releases may also interest you

at 12:05
Workspot Names Brad Tompkins New CEO as Company Readies for Rapid Scale-up
Workspot, the Enterprise VDI platform built for the multi-cloud and hybrid era, announced today that it has appointed Brad Tompkins as Chief Executive Officer (CEO), effective immediately. Tompkins previously served as the company's President and...

at 12:05
NEC X Unveils Next Wave of Tech Disruptors, Elev X! Ignite Cohort Batch 11
NEC X, the Silicon Valley-based innovation accelerator and venture studio backed by global IT leader NEC, today unveiled the standout startups selected to join Elev X! Ignite cohort Batch 11. The seven new startups were handpicked from more than 250...

at 12:05
HELIOS® by VirtualHealth Named Bronze Stevie® Award Winner in 2024 American Business Awards®
VirtualHealth is excited to share that its HELIOS platform was named the winner of a Bronze Stevie® Award in the Healthcare Technology Solution category in The 22nd Annual American Business Awards® today. More than 3,700 nominations were submitted...

at 12:00
eBay Launches 5th Annual Up & Running Grants Program, Awarding $500,000 to Small Businesses
Today, eBay is launching its 5th annual Up & Running Grants program ? a series of annual grants that reward 50 U.S. eBay sellers with tools and resources to grow their small businesses. In addition to a $10,000 reward, eBay is offering recipients a...

at 12:00
Immutable Launches The Main Quest, the Largest Ever Web3 Gaming Rewards Program
Immutable, the leading web3 gaming platform and ecosystem, today announced the launch of 'The Main Quest', the largest ever web3 gaming quest and rewards program. With up to $US50M in token rewards already secured for players and more to be...

at 12:00
Revolutionizing E-Commerce and Cryptocurrency Integration: $2 Million Seed Funding Secured by Moso
Moso, the groundbreaking shop-to-earn platform that seamlessly merges online shopping with cryptocurrency, proudly announces the successful completion of its $2 million seed funding round. This achievement marks a pivotal moment in Moso's journey,...

More news about Science and technology...


News published on and distributed by: